

## LIST OF TABLES

| TABLE NO.  | TABLE TITLE   | PAGE NO |
|------------|---|---------|
| Table 2.1  | p53 gene delivery vectors   | 22      |
| Table 2.2  | Various Potential Ligands for Targeting the Nano-constructs to Lung Cancer  | 25      |
| Table 3.1  | Preparation of working standard solution of $\beta$ galactosidase from stock solution   | 53      |
| Table 4.1  | Results observed during transformation of pCB6+ ARG p53 and pCMV-SPORT- $\beta$ -gal plasmid DNA  | 63      |
| Table 5.1  | Optimization of process and formulation parameters for optimized size of liposomes by Ethanol injection technique                                   | 79      |
| Table 5.2  | Effect of process and formulation parameters in liposome development by SCF technique   | 81      |
| Table 5.3  | Size and Zeta Potential of the Lipoplexes in HEPES buffer pH 8.0 at varying N/P ratio   | 86      |
| Table 5.4  | Particle Size and Zeta Potential of 6-Coumarin loaded Lipoplexes prepared by EI, TFH and SCF technique  | 90      |
| Table 5.5  | Transfection of $\beta$ galactosidase pDNA at different N/P ratios of liposomes prepared by TFH, EI and SCF technique at different DOTAP:DOPE ratio | 94      |
| Table 5.6  | Size and Zeta Potential of Tf attached Lipoplexes:  | 96      |
| Table 5.7  | $\beta$ -galactosidase pDNA expression of Tf attached Lipoplexes in H 1299 cell line  | 98      |
| Table 5.8  | % Cell viability of H 1299 cells after p53 formulations treatment   | 101     |
| Table 5.9  | Particle size of Lipoplexes before and after lyophilization   | 103     |
| Table 5.10 | Cytotoxicity of Formulations before and after lyophilization  | 103     |
| Table 5.11 | PPF and MMAD of the Lyophilized Liposomal and Lipoplex formulations   | 105     |

|            |  |     |
|------------|--|-----|
| Table 6.1  | Optimization Studies for Etoposide Liposomes   | 116 |
| Table 6.2  | Optimization Studies for Docetaxel Liposomes   | 117 |
| Table 6.3  | Lyophilization of ETP liposomes by cryoprotectants   | 119 |
| Table 6.4  | Lyophilization of DTX liposomes by cryoprotectants   | 119 |
| Table 6.5  | Release pattern of ETP and DTX Liposomes in PBS pH 7.4 and Acetate Buffer pH 5.4 release media                   | 120 |
| Table 6.6  | Size and Zeta Potential of Blank, ETP and DTX loaded lipoplexes  | 122 |
| Table 6.7  | Release pattern of ETP and DTX Lipoplexes in PBS pH 7.4 and Acetate Buffer pH 5.4 release media                  | 123 |
| Table 6.8  | Quantitative uptake of 6-Coumarin formulations by H 1299 and A 549 cell line                                     | 128 |
| Table 6.9  | Transfection of $\beta$ gal activity at different N/P ratios of blank lipoplexes in H 1299 and A 549 cell line.  | 132 |
| Table 6.10 | Effect of cytotoxic chemotherapeutic agents on $\beta$ gal cDNA cell transfection in H 1299 and A 549 cell lines | 134 |
| Table 6.11 | % Cell viability of H 1299 and A 549 cells after p53 and ETP / DTX formulations treatment                        | 137 |
| Table 6.12 | % stained H 1299 cells after Annexin V-FITC and PI staining demonstrating apoptotic and necrotic cells.          | 145 |
| Table 6.13 | % stained A 549 cells after Annexin V-FITC and PI staining demonstrating apoptotic and necrotic cells.           | 145 |
| Table 6.14 | Formulation parameters of liposomes and lipoplexes before after lyophilization                                   | 150 |
| Table 6.15 | FPF and MMAD of the Lyophilized Liposomal and Lipoplex formulations  | 152 |